- Reneo Pharmaceuticals and OnKure Announce Proposed Merger
- Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
- Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
- Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
- Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
- Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
- Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
- Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
- Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
- Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results
More ▼
Key statistics
On Thursday, Reneo Pharmaceuticals Inc (RPHM:NMQ) closed at 1.73, 76.51% above the 52 week low of 0.9801 set on Dec 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.80 |
---|---|
High | 1.85 |
Low | 1.70 |
Bid | 1.68 |
Offer | 1.83 |
Previous close | 1.73 |
Average volume | 946.22k |
---|---|
Shares outstanding | 33.42m |
Free float | 31.70m |
P/E (TTM) | -- |
Market cap | 57.82m USD |
EPS (TTM) | -2.17 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼